Recursion Pharmaceuticals a News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.11.24	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery (GlobeNewswire)
22.10.24	Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection (GlobeNewswire)
02.10.24	Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma (GlobeNewswire)
03.09.24	Recursion: REC-994 Meets Primary Endpoint Of Safety, Tolerability In 12-month Phase 2 Study (RTTNews)
03.09.24	Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability (GlobeNewswire)
11.08.24	Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
08.08.24	Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities (GlobeNewswire)
16.04.24	Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer (GlobeNewswire)
11.03.24	Recursion Announces Plans to Open New Office in London (GlobeNewswire)
04.01.24	Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline (GlobeNewswire)
09.11.23	Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology (GlobeNewswire)
13.07.23	Recursion kündigt Zusammenarbeit und Investition in Höhe von 50 Millionen USD von NVIDIA zur Beschleunigung bahnbrechender Modelle für die KI-gestützte Wirkstoffforschung an (GlobeNewswire)
12.07.23	Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery (GlobeNewswire)
10.05.23	Recursion schliesst Übernahmevereinbarungen für Cyclica und Valence zur Stärkung der Fähigkeiten in den Bereichen Chemie und generative KI ab (GlobeNewswire)
08.05.23	Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities (GlobeNewswire)
01.02.23	Recursion to Participate in Upcoming Investor Conference (PR Newswire)
26.01.23	Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day (PR Newswire)
20.12.22	Recursion to Participate in Upcoming Investor Conferences (PR Newswire)
08.11.22	Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results (PR Newswire)
02.11.22	Recursion to Participate in Upcoming Investor Conferences (PR Newswire)
25.10.22	Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB (PR Newswire)
13.09.22	Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 (PR Newswire)
01.09.22	Recursion to Participate in Upcoming Investor Conferences (PR Newswire)
18.08.22	Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum (PR Newswire)
09.08.22	Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results (PR Newswire)
21.07.22	Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis (PR Newswire)
20.06.22	Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference (PR Newswire)
02.06.22	Recursion to Participate in Upcoming Investor Conferences (PR Newswire)
07.12.21	Recursion Announces Collaboration With Roche, Genentech In Neuroscience And Oncology (RTTNews)
07.10.21	Recursion's REC-2282 Granted FDA Fast Track Designation For NF2-Mutated Meningiomas Treatment (RTTNews)
13.08.21	Recursion Reports Second Quarter 2021 Financials and Provides Business Updates (PR Newswire)
13.07.21	Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD (PR Newswire)
12.07.21	Recursion Opens Child Care Center to Support Employees (PR Newswire)
01.07.21	Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City (PR Newswire)
23.06.21	Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery (PR Newswire)
23.06.21	Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery (PR Newswire)
23.06.21	Recursion annonce une collaboration pluriannuelle avec Mila pour la découverte de médicaments grâce à l'intelligence artificielle (PR Newswire)
15.06.21	Recursion annonce sa première expansion multidisciplinaire d'envergure, à Toronto, dans le but de favoriser la découverte de médicaments adaptés à la technologie (PR Newswire)
15.06.21	Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery (PR Newswire)
15.06.21	Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Recursion Pharmaceuticals, Inc Registered Shs -A-

Aktien Top/Flop

Meistgelesene Nachrichten